Physician profile
Lawrence Ld Vu
NPI 1225040801
$2,910.94
in general payments reported to CMS, 2019-2025
26 companies · $536 in 2025
The $536 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $373 · 2021: $276 · 2022: $558 · 2023: $296 · 2024: $554 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $441.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $266.69 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $227.56 | 2020-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.92 | 2021-2022 | |
| Lilly USA, LLC | $178.54 | 2020-2025 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $161.47 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $132.62 | 2022-2025 | |
| Abbvie INC. | $130.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $118.87 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Astrazeneca Pharmaceuticals LP | $118.06 | 2019-2025 | Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $115.37 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Sanofi Pasteur INC. | $113.40 | 2019-2025 | |
| Dexcom, INC. | $97.66 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $97.39 | 2020-2025 | |
| Amgen INC. | $95.07 | 2019-2024 | Repatha, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.09 | 2023-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $72.53 | 2020-2022 | |
| Allergan, INC. | $61.89 | 2019-2020 | |
| Exact Sciences Corporation | $60.52 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $34.23 | 2019 | |
| Meridian Bioscience INC. | $29.31 | 2022-2023 | |
| Vbi Vaccine (Delaware) INC. | $24.58 | 2022 | |
| Viiv Healthcare Company | $24.57 | 2025 | Apretude |
| Novartis Pharmaceuticals Corporation | $20.44 | 2021 | |
| Eisai INC. | $17.56 | 2020 | |
| Krystal Biotech INC | $15.35 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.